Inflammatory mediators in gastrointestinal defense and injury

Experimental Biology and Medicine

Volumn 226, Issue 11, 2001, Pages 1003-1015

  Wallace, John L ^a   Ma, Li ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Inflammation; Leukotrienes; Nitric oxide; Prostaglandins; Ulcer disease

Indexed keywords

ARACHIDONIC ACID; CALCITONIN GENE RELATED PEPTIDE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; NEUROPEPTIDE Y; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 AGONIST; PROTEINASE ACTIVATED RECEPTOR 4; SUBSTANCE P; SYNTHETIC PEPTIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; COLITIS; COLON MUCOSA; DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; GASTROINTESTINAL DISEASE; HOST RESISTANCE; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PROSTAGLANDIN METABOLISM; RAT; SHORT SURVEY; TISSUE INJURY;

ANIMALIA;

EID: 0035757961     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020122601107     Document Type: Short Survey

References (172)

1. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASEB J 10:731-740, 1996.
2. + back-diffusion. Nature 313:51-54, 1985.
3. Paimela H, Goddard PJ, Silen W. Present views on restitution of gastrointestinal epithelium. Dig Dis Sci 40:2495-2496, 1995.
4. Holzer P, Livingston EH, Saria A, Guth PH. Sensory neurons mediate protective vasodilatation in rat gastric mucosa. Am J Physiol 260:G363-G370, 1991.
5. Beck PL, McKnight W, Lee SS, Wallace JL. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. Am J Physiol 265:G453-G458, 1993.
6. Ferraz JGP, McKnight W, Sharkey KA, Wallace JL. Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. Gastroenterology 108:1183-1191, 1995.
7. Wallace JL. Mechanisms of protection and healing: current knowledge and future research. Am J Med 110(Suppl 1):S19-S23, 2001.
8. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119:512-520, 2000.
9. Miller MJ, Sandoval M. Nitric oxide: III. A molecular prelude to intestinal inflammation. Am J Physiol 276:G795-G799, 1999.
10. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 99:607-611, 1990.
11. MacNaughton WK, Cirino G, Wallace JL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 45:1869-1876, 1989.
12. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:173-179, 1994.
13. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257:249-255, 1994.
14. Reuter BK, Cirino G, Wallace JL. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 55:PL1-PL8, 1994.
15. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109:524-530, 1995.
16. Kubes P, McCafferty D-M. Nitric oxide and intestinal inflammation. Am J Med 109:150-158, 2000.
17. Kanwar S, Wallace JL, Befus D, Kubes P. Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. Am J Physiol 266:G222-G229, 1994.
18. Kubes P. Nitric oxide modulates epithelial permeability in the feline small intestine. Am J Physiol 262:G1138-G1142, 1992.
19. Hogaboam CM, Befus AD, Wallace JL. Modulation of rat mast cell reactivity by IL-1β: divergent effects on nitric oxide and platelet-activating factor release. J Immunol 151:3767-3774, 1993.
20. Salvemini D, Masini E, Pistelli A, Mannaioni PF, Vane JR. Nitric oxide: a regulatory mediator of mast cell reactivity. J Cardiovasc Pharmacol 17:S258-S264, 1991.
21. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK. Peroxynitrite-induced rat colitis: a new model of colonic inflammation. Gastroenterology 105:1681-1688, 1993.
22. Miller MJS, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, Ye YZ, Rodi CP, Manning PT, Currie MG, Clark DA. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475-1483,1995.
23. Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 268:G673-G684, 1995.
24. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37:247-255, 1995.
25. Kubes P, Reinhardt PH, Payne D, Woodman RC. Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. Am J Physiol 269:G34-G41, 1995.
26. Wallace JL, Vergnolle N, Muscara MN, Asfaha S, Chapman K, McKnight W, Del Soldato P, Morelli A, Fiorucci S. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 117:557-566, 1999
27. Robert A. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prost Thrombox Res 2:507-520, 1976.
28. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235, 1971.
29. Wallace JL. Gastric ulceration: critical events at the neutrophil-endothelium interface. Can J Physiol Pharmacol 71:98-102, 1993.
30. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107:513-516, 1987.
31. 4 synthesis. Gastroenterology 101:18-27, 1992.
32. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 89:1162-1188, 1985.
33. Asako H, Kubes P, Wallace JL, Gaginella T, Wolf RE, Granger DN. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 262:G903-G908, 1992.
34. Asako H, Kubes P, Wallace JL, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 103:146-152, 1992.
35. Woolverton CJ, White JJ, Sartor RB. Eicosanoid regulation of acute intestinal vascular permeability induced by intravenous peptidoglycan polysaccharide polymers. Agents Actions 26:301-309, 1989.
36. 2. Biochem Biophys Res Commun 137:404-410, 1986.
37. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263:5380-5384, 1988.
38. Santucci L, Fiorucci S, Giansanti M, Brunori PM, DiMatteo FN, Morelli A. Pentoxifylline prevents indomethacin-induced acute mucosal damage in rats: role of tumour necrosis factor-α. Gut 35:909-915, 1994.
39. Spatafora M, Chiappara G, D'Amico D, Volpes D, Melis M, Pace E, Merendino A. Effect of indomethacin on the kinetics of tumour necrosis factor-α release and tumour necrosis factor-α gene expression by human blood monocyte. Pharmacol Res 23:247-257, 1991.
40. Martich GD, Dannen RL, Ceska M, Saffredini AF. Detection of interleukin-8 and tumour necrosis factor in normal humans after intravenous endotoxin administration: the effect of anti-inflammatory agents. J Exp Med 173:1021-1024, 1991.
41. Kunkel SL, Chensue SW. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Commun 128:892-897, 1985.
42. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 136:186-192, 1986.
43. Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl FA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A 80:4349-4353, 1983.
44. Haurand M, Floh L. Leukotriene formation by human polymorpho-nuclear leukocytes from endogenous arachidonate: physiological triggers and modulation by prostanoids. Biochem Pharmacol 38:2129-2137, 1989.
45. 2, dexamethasone, and IL-4. J Immunol 151:2166-2175, 1993.
46. Raud J. Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br J Pharmacol 99:449-454, 1990.
47. Hogaboam CM, Bissonnette EY, Chin BC, Befus AD, Wallace JL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 104:122-129, 1993.
48. Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Granulocytes: the culprit in ischemic damage to the intestine. Am J Physiol 253:H699-H703, 1987.
49. Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends Pharmacol Sci 13:129-131, 1992.
50. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci 33:6S-15S, 1988.
51. Wallace JL, Higa A, McKnight GW, MacIntyre DE. Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflammation 16:343-354, 1992.
52. Wong K, Freund F. Inhibition of n-formylmethiony-leucyl-phenyl-alanine induced respiratory burst in human neutrophils by adrenergic agonists and prostaglandins of the E series. Can J Physiol Pharmacol 59:915-920, 1981.
53. Gryglewski RJ, Szczeklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 36:4209-4212, 1987.
54. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 88:2692-2696, 1991.
55. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 25:249-265, 1992.
56. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci 1999;20:4-6.
57. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey K, MacNaughton M. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115:101-109, 1998.
58. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95:13313-13318, 1998.
59. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Testa R, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482, 1995.
60. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701, 1999.
61. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445-454, 1996.
62. Davies NM, Sharkey KA, Asfaha S, Macnaughton WK, Wallace JL. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 11:1101-1108, 1997.
63. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 128:1659-1666, 1999.
64. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 123:927-935, 1998.
65. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397, 1997.
66. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085, 1996.
67. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. J Am Med Assoc 284:1247-1255, 2000.
68. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528, 2000.
69. 4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut 34:742-747, 1993.
70. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. A pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 16:227-240, 1992.
71. Yoshida N, Takemura T, Granger DN, Anderson DC, Wolf RE, McIntire LV, Kvietys PR. Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Gastroenterology 105:715-724, 1993.
72. 4 concentrations in children with Helicobacter pylori colonization. Turk J Pediatr 41:335-339, 1999.
73. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453-460, 1984.
74. Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease. Gastroenterology 88:55-63, 1985.
75. 4 in rabbit colitis: relationship to inflammation. Gastroenterology 92:33-39, 1987.
76. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29-36, 1989.
77. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 258:G527-G534, 1990.
78. 4. Dig Dis Sci 32:1380-1388, 1987.
79. 4 potentiates colonic ulceration in the rat. Dig Dis Sci 35:622-629, 1990.
80. Bell CJ, Elliott EJ, Wallace JL, Redmond DM, Payne J, Li Z, O'Loughlin EV. Do eicosanoids cause colonic dysfunction in experimental E. coli 0157:H7 (EHEC) infection? Gut 46:806-812, 2000.
81. Stenson WF, Lauritsen K, Laursen LS, Rask-Madsen J, Jacobsen O, Naesdal J, Cort D, Goebell H, Peskar B, Hanauer S, Swanson L, Dube L, Rubin P. A clinical trial of Zileuton, a specific inhibitor of 5-lipoxygenase in ulcerative colitis. Gastroenterology 100:A253, 1991.
82. Bukhave K, Laursen LS, Lauritsen K, Rask-Masden J, Naesdal J, Jacobsen O, Goebell H, Peskar B, Cort D, Stenson W, Hanauer S. 5-Lipoxygenase inhibition in double-blind trial with zileuton: how much is sufficient in active ulcerative colitis? Gastroenterology 100:A200, 1991.
83. x-dependent alterations in leukocyte kinetics in vivo. Circ Res 77:879-887, 1995.
84. Wallace JL, McKnight GW, Keenan CM, Byles NIA, MacNaughton WK. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 98:1178-1186, 1990.
85. Rioux KP, Wallace JL. Mast cell activation augments gastric mucosal injury through a leukotriene-dependent mechanism. Am J Physiol 266:G863-G869, 1994.
86. Befus AD, Fujimaki H, Lee TDG, Swieter M. Mast cell polymorphism: present concepts, future directions. Dig Dis Sci 33:16S-24S, 1988.
87. Perdue MH, Ramage JK, Burget D, Marshall J, Masson S. Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Dig Dis Sci 34:724-731, 1989.
88. Higgs GA, Moncada S, Salmon JA, Seager K. The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol 89:1162-1188, 1985.
89. 4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. Microvas Res 41:367-375, 1991.
90. 2 induces ulceration of the gastric mucosa. Nature 292:472-474, 1981.
91. 2α, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 248:G580-G586, 1985.
92. Konturek SJ, Brzozowski T, Piastucki I, Radecki T, Dembinska-Kiec A. Role of prostaglandin and thromboxane biosynthesis in gastric necrosis produced by taurocholate and ethanol. Dig Dis Sci 28:154-160, 1983.
93. Walt RP, Kemp RT, Filipowicz B, Davies JG, Bhaskar NK, Hawkey CJ. Gastric mucosal protection with selective inhibition of thromboxane synthesis. Gut 28:541-544, 1987.
94. 2 in healing of gastric ulcers in rats. Jpn J Pharmacol 79:101-107, 1999.
95. 2 and prostaglandin catabolism in gastritis and gastric ulcer. Gut 27:1484-1492, 1986.
96. 2 biosynthesis in endotoxin-induced intestinal damage in the rat. Prostaglandins 38:319-333, 1989.
97. Hudson M, Chitolie A, Hutton RA, Smith MSH, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 38:733-737, 1996.
98. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AF, More L, Sim R, Pittilo RM, Rowles PM, Hudson M, Lewis AAM, Pounder RE. Granulomatous vasculitis in Crohn's disease. Gastroenterology 100:1279-1287, 1995.
99. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada J-R. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 98:269-277, 1990.
100. 2 receptor antagonist in an animal model of inflammatory bowel disease. Digestion 58:476-478, 1997.
101. Van Outryve M, Huble F, Van Eeghem P, De Vos M. Comparison of ridogrel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis. Gastroenterology 110:A1035, 1996.
102. Casellas F, Papo M, Guarner F, Antolin M, Segura RM, Armengol JR, Malagelada JR. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 7:221-226, 1995.
103. Skandalis N, Rotenberg A, Meuwissen S, de Groot GH, Ouwendijk RJT, Tan TG. Ridogrel for the treatment of mild to moderate ulcerative colitis. Gastroenterology 110:A1016, 1996.
104. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol 259: C697-C708, 1990.
105. Rosam AC, Wallace JL, Whittle BJR. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 319:54-56, 1986.
106. Gonzalez-Crussi F, Hsueh W. Experimental model of ischemic bowel necrosis. Am J Pathol 112:127-135, 1983.
107. Wallace JL, Whittle BJR. Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins 31:989-998, 1986.
108. Wallace JL, Steel G, Whittle BJR, Lagente V, Vargaftig B. Evidence for platelet-activatIng factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology 93:765-773, 1987.
109. Wallace JL, Hogaboam CM, McKnight GW. Platelet-activating factor mediates gastric damage induced by hemorrhagic shock. Am J Physiol 259:G140-G146, 1990.
110. Kubes P, Ibbotson G, Russell J, Wallace JL, Granger DN. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol 259:G300-G305, 1990.
111. Kubes P, Suzuki M, Granger DN. Platelet-activating factor-induced microvascular dysfunction: role of adherent leukocytes. Am J Physiol 258:G158-G163, 1990.
112. Sun XM, Qu XW, Huang W, Granger DN, Bree M, Hsueh W. Role of leukocyte β2-integrin in PAF-induced shock and intestinal injury. Am J Physiol 270:G184-G190, 1996.
113. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 110:529-540, 1990.
114. Hsueh W, Gonzalez-Crussi F, Arroyave JL. Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia. FASEB J 1:403-405, 1987.
115. 4 by isolated, perfused rat small intestine in response to platelet-activating factor. J Clin Invest 78:108-114, 1986.
116. Hogaboam CM, Befus AD, Wallace JL. Intestinal platelet-activating factor synthesis during Nippostrongylus brasiliensis infection in the rat. J Lipid Mediators 4:211-224, 1991.
117. Hogaboam CM, Wallace JL. Intestinal PAF synthesis: the role of the mast cell. J Lipid Mediators 10:103-105, 1994.
118. Hanglow AC, Bienenstock J, Perdue MH. Effects of plateletactivating factor on ion transport in isolated rat jejunum. Am J Physiol 257:G845-G850, 1989.
119. Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazin e and prednisolone. Gastroenterology 95:1167-1172, 1988.
120. Wallace JL. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol 66:422-425, 1988.
121. Wallace JL, Braquet P, Ibbotson GC, MacNaughton WK, Cirino G. Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease. J Lipid Med 1:13-23, 1989.
122. Will PC, Thomas TK, Iverson L, Buckman D, Weis W, Wilson C, Srivastava A. Platelet activating factor as a proinflammatory mediator in acetic acid-induced colitis in the rat. Agents Actions 34:181-184, 1991.
123. Denizot Y, Chaussade S, Nathan N, Colombel JF, Bossant M-J, Cherouki N, Benveniste J, Couturier D. PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig Dis Sci 37:432-437, 1992.
124. Ferraris L, Karmeli F, Eliakim R, Klein J, Fiocchi C, Rachmilewitz D. Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut 34:665-668, 1993.
125. Reinshagen M, Patel A, Sottili M, French S, Sternini C, Eysselein VE. Action of sensory neurons in an experimental rat colitis model of injury and repair. Am J Physiol 270:G79-G86, 1996.
126. Stead RH, Dixon MF, Bramwell NH, Riddell RH, Bienenstock J. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 97:575-585, 1989.
127. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol 135:1331-1337, 1985.
128. Wallace JL, McKnight GW, Befus AD. Capsaicin-induced hyperemia in the stomach: possible contribution of mast cells. Am J Physiol 263:G209-G214, 1992.
129. Sung C-P, Arleth AJ, Feuerstein GZ. Neuropeptide Y up-regulates the adhesiveness of human endothelial cells for leukocytes. Circ Res 68:314-318, 1991.
130. Raithel M, Schneider HT, Hahn EG. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol 34:496-503, 1999.
131. Matis WL, Lavker RM, Murphy GF. Substance P induces the expression of an endothelial-leukocyte adhesion molecule by microvascular endothelium. J Invest Dermatol 94:492-495, 1990.
132. Wershil BK, Wang Z-S, Galli SJ. Gastric inflammation in the mouse: evidence of mast cell-dependent neutrophil infiltration during IgE-dependent or substance P-induced inflammation. Gastroenterology 102:A712, 1992.
133. Dinarello CA. Cytokines: interleukin-1 and tumour necrosis factor (cachectin). In: Gallin JI, Goldstein IM, Snyderman R, Eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, pp195-208, 1988.
134. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325, 1994.
135. Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Mediators Inflamm 6:95-103, 1997.
136. 2 synthesis by the stomach, and retards gastric emptying. Life Sci 48:123-134, 1990.
137. Wallace JL, Keenan CM, Cucala M, Mugridge KG, Parente L. Mechanisms underlying the protective effects of interleukin-1 in experimental NSAID gastropathy. Gastroenterology 102:1176-1185, 1992.
138. Shibasaki T, Yamauchi N, Hotta M, Imaki T, Oda T, Ling N, Demura H. Interleukin-1 inhibits stress-induced gastric erosion in rats. Life Sci 48:2267-2273, 1991.
139. Wallace JL, Keenan CM, Mugridge KG, Parente L. Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1β. Eur J Pharmacol 186:279-284, 1990.
140. Uehara A, Okumura T, Sekiya C, Okamura K, Takasugi Y, Namiki M. Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. Biochem Biophys Res Commun 162:1578-1584, 1989.
141. Wallace JL, Cucala M, Mugridge K, Parente L. Secretagoguespecific effects of interleukin-1 on gastric acid secretion. Am J Physiol 261:G559-G564, 1991.
142. Saperas ES, Yang H, Rivier C, Tache Y. Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Gastroenterology 99:1599-1606, 1990.
143. Wu KK, Sanduja R, Tsai AL, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A 88:2384-2387, 1991.
144. Palmer RM, Hickery MS, Charles IG, Moncada S, Bayliss MT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 193:398-405, 1993.
145. Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace JL. Tumour necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 270:G42-G48, 1996.
146. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor-α in childhood chronic inflammatory bowel disease. Gut 32:913-917, 1991.
147. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor-α in stool as a marker of intestinal inflammation. Lancet 339:89-91, 1992.
148. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709, 1993.
149. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135, 1995.
150. Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P. Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001-2003. Int J Colorectal Dis 16:1-11, 2001.
151. Stordeur P, Goldman M. Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. Int Rev Immunol 16:501-522, 1998.
152. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 11:165-190, 1993.
153. Casatell MA, Meda L, Gasperini S, Bonora S. Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179:1695-1699, 1994.
154. Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, Sinnott PJ, Hutchinson IV. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54:386-390, 1999.
155. Akagi S, Hiyama E, Imamura Y, Takesue Y, Matsuura Y, Yokoyama T. Interleukin-10 expression in intestine of Crohn's disease. Int J Mol Med 5:389-395, 2000.
156. Nicolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42:470-476, 1998.
157. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274, 1993.
158. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis-secreting interleukin-10. Science 289:1352-1355, 2000.
159. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 46:344-349, 2000.
160. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274:C1429-C1452, 1998.
161. Hollenberg MD. Protease-activated receptors: PAR4 and counting: how long is the course? Trends Pharmacol Sci 20:271-273, 1999.
162. Saifeddine M, Al-Ani B, Cheng CH, Wang L, Hollenberg MD. Rat proteinase-activated receptor-2 (PAR2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 118:521-530, 1996.
163. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127:1083-1090, 1999.
164. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152, 2001.
165. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6:151-158, 2000.
166. Corvera CU, Dery O, McConalogue K, Gamp P, Thoma M, Al-Ani B, Caughey GH, Hollenberg MD, Bunnett NW. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. J Physiol (Lond) 517:741-756, 1999.
167. Green BT, Bunnett NW, Kulkami-Narla A, Steinhoff M, Brown DR. Intestinal type-2 proteinase-activated receptors: expression in opioidsensitive secretomotor neural circuits that mediate epithelial transport. J Pharm Exp Ther 295:410-416, 2000.
168. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD. A protective role for protease-activated receptors in the airways. Nature 398:156-160, 1999.
169. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima H, Yanoma S, Yasumitsu H, Miyazaki K. Expression of trypsin in vascular endothelial cells. FEBS Lett 409:442-448, 1997.
170. Molino M, Bamathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF. Interactions of mast cell tryptase with thrombin receptors and PAR2. J Biol Chem 272:4043-4049, 1997.
171. Stead RH, Tomioka M, Quinonez G, Simon GT, Felten SY, Bienenstock J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Nat Acad Sci U S A 84:2975-2979, 1987.
172. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci 46:607-617, 1990.